

Ovarian Vein Embolization

Table of Content	Effective Date	6/1999
<u>Purpose</u> Description & Definitions		
Criteria	<u>Next Review Date</u>	6/15/2024
<u>Coding</u> <u>Document History</u>	Coverage Policy	Surgical 202
References	Manaian	
<u>Special Notes</u> <u>Keywords</u>	<u>Version</u>	4

All requests for authorization for the services described by this medical policy will be reviewed per Early and Periodic Screening, Diagnostic and Treatment (EPSDT) guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to by medically necessary to correct or ameliorate the member's condition. Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.*.

-						
P	11r	n	0	C	Δ	٠
1	սւ	D	U	0	C	•

This policy addresses Ovarian Vein Embolization.

Description & Definitions:

Ovarian Vein Embolization is a procedure used to help resolve a painful condition called pelvic congestion syndrome.

Criteria:

Ovarian Vein Embolization is considered medically necessary for pelvic congestion syndrome (PCS) with all of the following:

- Individual with a definitive diagnostic venography, computerized tomography (CT) scan, or Magnetic resonance • imaging (MRI)
- Individual with failed trial of appropriate pharmacotherapy

Ovarian Vein Embolization is considered not medically necessary for any use other than those indicated in clinical criteria.

Coding:	
Medically nece	essary with criteria:
Coding	Description
37241	Vascular embolization or occlusion, inclusive of all radiological supervision and interpretation, intraprocedural roadmapping, and imaging guidance necessary to complete the intervention; venous, other than hemorrhage (eg, congenital or acquired venous malformations, venous and capillary hemangiomas, varices, varicoceles)

Considered Not Medically Necessary:

Coding	Description
	None

U.S. Food and Drug Administration (FDA) - approved only products only.

Document History:

Revised Dates:

- 2020: January
- 2014: May, June
- 2013: April, October
- 2012: January, April, September
- 2011: December
- 2008: April, October
- 2004: May, July
- 2003: July
- 2001: August
- 1999: September

Reviewed Dates:

- 2023: June
- 2022: June
- 2021: July
- 2020: August
- 2019: April
- 2018: August
- 2017: November
- 2016: June
- 2015: October
- 2011: April
- 2010: April
- 2009: April
- 2007: October
- 2006: June, September
- 2005: July, December
- 2003: June

Effective Date:

• June 1999

References:

Specialty Association Guidelines; Government Regulations; Winifred S. Hayes, Inc; UpToDate; Literature Review; Specialty Advisors; National Coverage Determination (NCD); Local Coverage Determination (LCD).

(2023). Centers for Medicare and Medicaid Services. CMS.gov. (2023). Retrieved 6.12.2023. https://www.cms.gov/medicare-coverage-database/searchresults.aspx?hcpcsOption=code&hcpcsStartCode=37241&hcpcsEndCode=37241&sortBy=title&areald=all&docTy pe=6,3,5,1,F,P&contractOption=all

(2023). 37241 or Embolization. US Food and Drug Administration. Vascular and Neurovascular Embolization Devices - Class II Special Controls Guidance Document for Industry and FDA Staff. FDA.gov. (2023). https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emittingproducts/vascular-and-neurovascular-embolization-devices-class-ii-special-controls-guidance-document-industry (2023). Ovarian Vein Embolization. Hayes, a symplr company. (4.232023). Retrieved 6.12.2023. https://evidence.hayesinc.com/report/dir.veinembolization4816

(2023). 37241. Ovarian and Internal Iliac Vein Embolization. ACG: A-05674. MCG. Informed Care Strategies. (8.31.2022). Retrieved 6.12.2023. https://careweb.careguidelines.com/ed26/index.html

(2023). Embolization. DMAS. An Agency of the Commonwealth of Virginia. (2023). Retrieved 6.12.2023. https://vamedicaid.dmas.virginia.gov/pdf_chapter/physician-practitioner#gsc.tab=0&gsc.q=embolization&gsc.sort=

(2023). General Clinical Guideline. Caelon. (3.1.2023). Retrieved 6.12.2023. https://guidelines.carelonmedicalbenefitsmanagement.com/pdf-general-clinical-guideline-2023-03-01/

(2023). Treatment Options for Pelvic Congestion Syndrome. VaricoseVeins.org. (10.28.2016). Retrieved 6.12.2023. https://varicoseveins.org/blog/2016/10/treatment-options-pelvic-congestion-syndrome

(2023). Joh, M., Grewal, S., Gupta, R. Ovarian Vein Embolization: How and When Should It Be Done? Techniques in Vascular and Interventional Radiology. (3.2021). Retrieved 6.12.2023. https://doi.org/10.1016/j.tvir.2021.100732

(2022). Retrieved May 18, 2022, from EncoderPro: https://www.encoderpro.com

Efficacy of endovascular treatment for pelvic congestion syndrome. (2016). Retrieved May 19, 2022, from SOCIETY FOR VASCULAR SURGERY (SVS) / AMERICAN VENOUS FORUM (AVF): https://www.jvsvenous.org/article/S2213-333X(16)00006-8/fulltext#relatedArticles

Vulvovaginal varicosities and pelvic congestion syndrome. (2019, Nov 18). Retrieved May 18, 2022, from UpToDate: https://www.uptodate.com/contents/vulvovaginal-varicosities-and-pelvic-congestion-syndrome?search=ovarian%20embolization&source=search_result&selectedTitle=3~150&usage_type=default&di splay_rank=3

Special Notes: *

This medical policy express Sentara Health Plan's determination of medically necessity of services, and they are based upon a review of currently available clinical information. These policies are used when no specific guidelines for coverage are provided by the Department of Medical Assistance Services of Virginia (DMAS). Medical Policies may be superseded by state Medicaid Plan guidelines. Medical policies are not a substitute for clinical judgment or for any prior authorization requirements of the health plan. These policies are not an explanation of benefits.

Medical policies can be highly technical and complex and are provided here for informational purposes. These medical policies are intended for use by health care professionals. The medical policies do not constitute medical advice or medical care. Treating health care professionals are solely responsible for diagnosis, treatment and medical advice. Sentara Health Plan members should discuss the information in the medical policies with their treating health care professionals. Medical technology is constantly evolving and these medical policies are subject to change without notice, although Sentara Health Plan will notify providers as required in advance of changes that could have a negative impact on benefits.

The Early and Periodic Screening, Diagnostic and Treatment (EPSDT) covers services, products, or procedures for children, if those items are determined to be medically necessary to "correct or ameliorate" (make better) a defect, physical or mental illness, or condition (health problem) identified through routine medical screening or examination, regardless of whether coverage for the same service or support is an optional or limited service under the state plan. Children enrolled in the FAMIS Program are not eligible for all EPSDT treatment services. All requests for authorization for the services described by this medical policy will be reviewed per EPSDT guidelines. These services may be authorized under individual consideration for Medicaid members under the age of 21-years if the services are judged to by medically necessary to correct or ameliorate the member's condition. *Department of Medical Assistance Services (DMAS), Supplement B - EPSDT (Early and Periodic Screening, Diagnosis and Treatment) Manual.* Surgical 202

Keywords:

Pelvic embolization, ovarian vein, embolization pelvic congestion syndrome, PCS, SHP Ovarian Vein Embolization, Surgical 202